208 related articles for article (PubMed ID: 1703070)
21. [Salazosulfapyridine and 5-aminosalicylic acid agents for the treatment of ulcerative colitis].
Aihara H; Hiwatashi N
Nihon Rinsho; 1999 Nov; 57(11):2476-80. PubMed ID: 10572415
[TBL] [Abstract][Full Text] [Related]
22. Forskolin inhibits the release of histamine from human basophils and mast cells.
Marone G; Columbo M; Triggiani M; Vigorita S; Formisano S
Agents Actions; 1986 Apr; 18(1-2):96-9. PubMed ID: 2425602
[TBL] [Abstract][Full Text] [Related]
23. The effects of anti-asthma drugs on mediator release from cultured human mast cells.
Shichijo M; Inagaki N; Nakai N; Kimata M; Nakahata T; Serizawa I; Iikura Y; Saito H; Nagai H
Clin Exp Allergy; 1998 Oct; 28(10):1228-36. PubMed ID: 9824389
[TBL] [Abstract][Full Text] [Related]
24. Modulation of human colonic arachidonic acid metabolism by sulfasalazine.
Hawkey CJ; Boughton-Smith NK; Whittle BJ
Dig Dis Sci; 1985 Dec; 30(12):1161-5. PubMed ID: 2866075
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of IgE-mediated mast cell degranulation by sulphasalazine.
Barrett KE; Tashof TL; Metcalfe DD
Eur J Pharmacol; 1985 Jan; 107(2):279-81. PubMed ID: 2579829
[TBL] [Abstract][Full Text] [Related]
26. Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin.
Cohan VL; Undem BJ; Fox CC; Adkinson NF; Lichtenstein LM; Schleimer RP
Am Rev Respir Dis; 1989 Oct; 140(4):951-4. PubMed ID: 2478059
[TBL] [Abstract][Full Text] [Related]
27. Effect of c-kit ligand, stem cell factor, on mediator release by human intestinal mast cells isolated from patients with inflammatory bowel disease and controls.
Bischoff SC; Schwengberg S; Wordelmann K; Weimann A; Raab R; Manns MP
Gut; 1996 Jan; 38(1):104-14. PubMed ID: 8566835
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of antibody secretion by 5-aminosalicylic acid.
MacDermott RP; Schloemann SR; Bertovich MJ; Nash GS; Peters M; Stenson WF
Gastroenterology; 1989 Feb; 96(2 Pt 1):442-8. PubMed ID: 2562949
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the anti-inflammatory effect of FK-506 on human mast cells.
de Paulis A; Cirillo R; Ciccarelli A; de Crescenzo G; Oriente A; Marone G
J Immunol; 1991 Dec; 147(12):4278-85. PubMed ID: 1721644
[TBL] [Abstract][Full Text] [Related]
30. Leukotrienes in Crohn's disease: effect of sulfasalazine and 5-aminosalicylic acid.
Dreyling KW; Hoppe U; Peskar BA; Schaarschmidt K; Peskar BM
Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():339-43. PubMed ID: 2889333
[No Abstract] [Full Text] [Related]
31. Inhibition of IgE-mediated release of histamine and peptide leukotriene from human basophils and mast cells by forskolin.
Marone G; Columbo M; Triggiani M; Cirillo R; Genovese A; Formisano S
Biochem Pharmacol; 1987 Jan; 36(1):13-20. PubMed ID: 2432900
[TBL] [Abstract][Full Text] [Related]
32. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli.
Benyon RC; Robinson C; Church MK
Br J Pharmacol; 1989 Jul; 97(3):898-904. PubMed ID: 2474353
[TBL] [Abstract][Full Text] [Related]
33. Actions of sulfasalazine and 5-aminosalicylic acid as reactive oxygen scavengers in the suppression of bile acid-induced increases in colonic epithelial cell loss and proliferative activity.
Craven PA; Pfanstiel J; Saito R; DeRubertis FR
Gastroenterology; 1987 Jun; 92(6):1998-2008. PubMed ID: 2883067
[TBL] [Abstract][Full Text] [Related]
34. Effect of sulphasalazine and balsalazide on histamine release from mast cells.
Peh KH; Wan BC; Assem ES; Pearce FL
Inflamm Res; 2007 Apr; 56 Suppl 1():S9-10. PubMed ID: 17806157
[No Abstract] [Full Text] [Related]
35. Anti-inflammatory effect of FK-506 on human skin mast cells.
de Paulis A; Stellato C; Cirillo R; Ciccarelli A; Oriente A; Marone G
J Invest Dermatol; 1992 Dec; 99(6):723-8. PubMed ID: 1281861
[TBL] [Abstract][Full Text] [Related]
36. Isoproterenol-induced inhibition of immunoglobulin E-mediated release of histamine and arachidonic acid metabolites from the human lung mast cell.
Undem BJ; Peachell PT; Lichtenstein LM
J Pharmacol Exp Ther; 1988 Oct; 247(1):209-17. PubMed ID: 2459368
[TBL] [Abstract][Full Text] [Related]
37. Control mechanisms of mediator release in human basophils and mast cells.
Marone G
Immunol Invest; 1988; 17(8-9):707-45. PubMed ID: 2465995
[No Abstract] [Full Text] [Related]
38. Effect of CC chemokines on mediator release from human skin mast cells and basophils.
Hartmann K; Beiglböck F; Czarnetzki BM; Zuberbier T
Int Arch Allergy Immunol; 1995 Nov; 108(3):224-30. PubMed ID: 7580286
[TBL] [Abstract][Full Text] [Related]
39. Oxatomide inhibits the release of proinflammatory mediators from human basophils and mast cells.
Patella V; de Crescenzo G; Marino O; Spadaro G; Genovese A; Marone G
Int Arch Allergy Immunol; 1996 Sep; 111(1):23-9. PubMed ID: 8753840
[TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of human mast cells and basophils. Effects of a putative 5-lipoxygenase inhibitor.
Cohan V; McKenzie-White J; Triggiani M; Massey W; Kagey-Sobotka A; Lichtenstein LM
Biochem Pharmacol; 1989 Dec; 38(24):4455-9. PubMed ID: 2481451
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
